scispace - formally typeset
C

Christopher F. Martin

Researcher at University of North Carolina at Chapel Hill

Publications -  123
Citations -  6399

Christopher F. Martin is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Inflammatory bowel disease & Odds ratio. The author has an hindex of 40, co-authored 123 publications receiving 5351 citations.

Papers
More filters
Journal ArticleDOI

Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease

TL;DR: Inflammatory bowel disease is associated with an increased incidence of melanoma and nonmelanoma skin cancer, and the risk of NMSC is increased by use of biologics and thiopurines, respectively, and patients with IBD should be counseled and monitored for skin cancer.
Journal ArticleDOI

Prevalence of eosinophilic esophagitis in the United States.

TL;DR: Despite its relatively recent description, EoE is frequently diagnosed in the United States, with an estimated prevalence of 56.7/100,000 persons, which depends on the accuracy of the International Classification of Diseases, 9th revision code, but it could be an underestimate.
Journal ArticleDOI

A High-Fiber Diet Does Not Protect Against Asymptomatic Diverticulosis

TL;DR: A high-fiber diet and increased frequency of bowel movements are associated with greater, rather than lower, prevalence of diverticulosis, and Hypotheses regarding risk factors for asymptomatic diverticus should be reconsidered.
Journal ArticleDOI

Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized Trial

Anne McTiernan, +62 more
TL;DR: Use of up to 2 years of estrogen plus progestin was associated with increases in mammographic density and abnormal findings over a 1-year and 2-year period.
Journal ArticleDOI

Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years

TL;DR: The noninvestigational experience suggests patients with stage III CC ≥ 75 years of age may anticipate a survival benefit from adjuvant chemotherapy, and use of adjUvant chemotherapy after the age of 75 years merits consideration in discussions that weigh individual risks and preferences.